| Catalog Number | Product | Size | Price | |
|---|---|---|---|---|
| C3099 | Human Thy1-CHO-K1 Stable Cell Line | 2 vials | $3950 | Order |
| Catalog Number | C3099 |
|---|---|
| Cell Line Name | Human Thy-1-CHO-K1 stable cell line |
| Accession Number | NM_006288.5 |
| Host Cell | CHO-K1 |
| Quantity | Two vials of frozen cells (2x106 per vial) |
| Culture Medium | DMEM with 10% FBS, 4 µg/ml puromycin |
| Freezing Medium | 90% FBS and 10% DMSO |
| Storage | Liquid nitrogen |
| Product Datasheet: | Download PDF |
Detection of human Thy expression on human Thy1-CHO-K1 stable cells (A) and CHO-K1 stable cells (B) using PE-anti-human-Thy1 Ab (Cat. #12-0909-41).
THY1 (CD90) is a glycoprotein involved in cell adhesion and signaling, primarily expressed on T lymphocytes, fibroblasts, and neurons. It plays a key role in immune responses, tissue repair, and stem cell regulation. THY1 is essential for cell-cell adhesion, migration, and signal transduction, contributing to T cell activation, stem cell differentiation, and tissue regeneration, as well as modulating processes like survival and apoptosis. It is expressed in various tissues, including T cells, fibroblasts, neurons, and mesenchymal stem cells, where it is crucial for self-renewal. Thy-1 expression is dysregulated in several cancers. It is often overexpressed in certain tumors, such as gliomas, melanomas, and some leukemias, while downregulated in others, including prostate and breast cancers. Its role in cancer progression is context-dependent, influencing tumor growth, metastasis, and angiogenesis. Thy-1 is being explored as a potential therapeutic target due to its involvement in cancer progression and immune modulation. Targeting Thy-1 could inhibit tumor growth, enhance immune responses, or modulate fibrosis in diseases like idiopathic pulmonary fibrosis.
Sauzay C, Voutetakis K, Chatziioannou A, Chevet E, Avril T. Front Cell Dev Biol. 7:66. 2019.
Kumar A, Bhanja A, Bhattacharyya J, Jaganathan BG. Tumour Biol. 37 9:11611-11622. 2016. Lobba ARM, Carreira ACO, Cerqueira OLD, Fujita A, DeOcesano-Pereira C, Osorio CAB, Soares FA, Rameshwar P, Sogayar MC. PLoS One. 13 6:e0199254. 2018.